Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The disease has similar prevalence across high-income and low- and middle-income nations.
Unexpectedly, liver steatosis was also associated with a greater chance of achieving HBsAg seroclearance.
The diabetes medication, alone or in combination regimens, led to improvements in NASH and fibrosis.
A Mediterranean diet could help reduce the risk of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
New guidelines recommend focusing on healthy foods but don’t restrict added sugars or alcohol as much as some experts had hoped.
COVID-19, FDA drug approvals and new approaches to treatment and quality of life stood out among this year’s top stories.
Areas with lower population density have not seen the same slowdown as urban areas.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.
Those with NAFLD or NASH and cirrhosis should undergo regular screening.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.